The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Medications safety pharmacoeconomics-related issues
Abstract
Abstract The cost of drug-related problems (DRPs), medication errors, counterfeit and substandard medications, and medication abuse and misuse is high worldwide and affects the health expenditure. Pharmacoeconomics play an important role in the medication safety practice, it can be used to estimate the cost of adverse drug reactions, DRPs, medication errors, and the impact of medication safety practice in reducing the health expenditure. This chapter aims to discuss the medication safety pharmacoeconomic-related issues and budget requirements and types for establishing a strong medications safety system. Study of the direct and indirect cost of medications safety issues is very important and highly recommended. Study of the economic impact of medication safety systems and practices on reducing the health expenditure is very important and highly recommended. Study of the impact of medications safety interventions on reducing the health expenditure is very important and highly recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Role of Cost-effectiveness Analysis in Health and Medicine
Russell, L. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140060028 · Cited by 1,167
Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness Model
Ernst, F. R., & Grizzle, A. J. (2001) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)31229-3 · Cited by 849
Clarification of Terminology in Drug Safety
Aronson, J. K., & Ferner, R. E. (2005) · Drug Safety · doi:10.2165/00002018-200528100-00003 · Cited by 328
The Role of Cost-Consequence Analysis in Healthcare Decision-Making
Mauskopf, J. A., Paul, J. E., Grant, D. M., & Stergachis, A. (1998) · PharmacoEconomics · doi:10.2165/00019053-199813030-00002 · Cited by 243
Clinical and Economic Impact of Adverse Drug Reactions in Hospitalized Patients
Suh, D.-C., Woodall, B. S., Shin, S.-K., & Hermes-De Santis, E. R. (2000) · The Annals of Pharmacotherapy · doi:10.1345/1542-6270(2000)034<1373:caeioa>2.0.co;2 · Cited by 230
Snyder, R. A., Abarca, J., Meza, J. L., Rothschild, J. M., Rizos, A., & Bates, D. W. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1423 · Cited by 218
Counting the Costs of Drug-Related Adverse Events
White, T. J., Arakelian, A., & Rho, J. P. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915050-00003 · Cited by 197
Assessing the Economic Impact of Adverse Drug Effects
Rodríguez-Monguió, R., Otero, M. J., & Rovira, J. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321090-00002 · Cited by 177
The importance of pharmacovigilance
Mehta, R. M. (2017) · Drug Designing Open Access · Cited by 170
Economic impact of medication error: a systematic review
Walsh, E. K., Hansen, C. R., Sahm, L. J., Kearney, P. M., Doherty, E., & Bradley, C. P. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4188 · Cited by 164
Metadata
- Authors
- Al-Worafi, Y. M.
- Venue
- Drug Safety in Developing Countries
- Publisher
- Elsevier
- Published
- 2020
- Pages
- 187-195
- OpenAlex
- W3034102747
- Cited by
- 367
- References
- 15
- FWCI
- 98.66
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medications safety pharmacoeconomics-related issues. https://app.cochat.ai/papers/10.1016/b978-0-12-819837-7.00016-9
- The paper
- Al-Worafi, Y. M. (2020). Medications safety pharmacoeconomics-related issues. Drug Safety in Developing Countries. https://doi.org/10.1016/b978-0-12-819837-7.00016-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.